Adamis Pharmaceuticals (ADMP) Given a $14.00 Price Target by Maxim Group Analysts

Adamis Pharmaceuticals (NASDAQ:ADMP) received a $14.00 price target from equities researchers at Maxim Group in a report issued on Tuesday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Maxim Group’s price target would suggest a potential upside of 201.08% from the company’s current price.

ADMP has been the subject of several other reports. ValuEngine downgraded shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. B. Riley set a $10.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 15th. Raymond James Financial started coverage on shares of Adamis Pharmaceuticals in a research report on Tuesday, September 12th. They issued an “outperform” rating and a $7.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $10.33.

Shares of Adamis Pharmaceuticals (ADMP) opened at $4.65 on Tuesday. The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06. Adamis Pharmaceuticals has a 1 year low of $2.55 and a 1 year high of $6.45.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Allied Advisory Services Inc. acquired a new stake in shares of Adamis Pharmaceuticals in the second quarter valued at approximately $114,000. Stonebridge Capital Advisors LLC raised its position in shares of Adamis Pharmaceuticals by 22.2% in the second quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock valued at $143,000 after buying an additional 5,000 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Adamis Pharmaceuticals by 131.0% in the third quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock valued at $143,000 after buying an additional 15,577 shares in the last quarter. Wells Fargo & Company MN acquired a new stake in shares of Adamis Pharmaceuticals in the second quarter valued at approximately $169,000. Finally, IFP Advisors Inc raised its position in shares of Adamis Pharmaceuticals by 2,245.6% in the second quarter. IFP Advisors Inc now owns 34,433 shares of the specialty pharmaceutical company’s stock valued at $179,000 after buying an additional 32,965 shares in the last quarter. Institutional investors own 16.73% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Adamis Pharmaceuticals (ADMP) Given a $14.00 Price Target by Maxim Group Analysts” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2017/12/05/maxim-group-analysts-give-adamis-pharmaceuticals-admp-a-14-00-price-target.html.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply